Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker Sells 5,578 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 5,578 shares of the stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares of the company's stock, valued at $1,561,172.44. This represents a 8.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pacira BioSciences Trading Down 2.1%

Shares of Pacira BioSciences stock traded down $0.55 during trading hours on Monday, hitting $25.42. The company's stock had a trading volume of 552,134 shares, compared to its average volume of 973,200. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -12.52 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $29.95. The firm has a fifty day moving average of $25.53 and a 200-day moving average of $23.41.

Institutional Trading of Pacira BioSciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC raised its position in Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after acquiring an additional 1,208 shares in the last quarter. Ancora Advisors LLC acquired a new position in shares of Pacira BioSciences in the fourth quarter worth $26,000. Caitlin John LLC boosted its stake in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Pacira BioSciences during the first quarter worth approximately $51,000. Finally, Brooklyn Investment Group boosted its holdings in shares of Pacira BioSciences by 372.2% during the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock worth $56,000 after purchasing an additional 1,764 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on PCRX. Needham & Company LLC dropped their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Barclays increased their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Wall Street Zen raised Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday. Finally, HC Wainwright increased their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.